Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05705531 · ClinicalTrials.gov registry record
A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma
A clinical trial of Classic Hodgkin Lymphoma and Clonal Hematopoiesis, sponsored by Children's Oncology Group.
- Recruiting
- Registry status
- 190
- Enrollment target
- 20
- Study locations
NCT05705531: Recruiting study of Classic Hodgkin Lymphoma and Clonal Hematopoiesis, sponsored by Children's Oncology Group.
NCT05705531 is a study of Classic Hodgkin Lymphoma and Clonal Hematopoiesis that is actively recruiting participants, run by Children's Oncology Group. The registered enrollment target is 190 participants, below the 232-participant average among 9 other Classic Hodgkin Lymphoma trials with a reported enrollment target (18% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05705531, a study of Classic Hodgkin Lymphoma and Clonal Hematopoiesis, is actively recruiting participants, sponsored by Children's Oncology Group.
- RECRUITING
- Registry status
- 190 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study assesses how blood cell growth patterns (clonal hematopoiesis) relate to heart health or cardiovascular disease (CVD) after treatment in patients with Hodgkin lymphoma. In some patients, cancer treatment at a young age may lead to later complications, including problems with heart health. Checking for blood cell growth patterns called therapy-related clonal hematopoiesis (t-CH) can help predict who might be at risk for heart health problems after Hodgkin lymphoma treatment. If doctors know who may be at greater risk for developing later heart complications, then they can more closely monitor those patients to prevent or detect heart complications early.
Primary Outcome
Measured in the blood of eligible participants who were previously treated with anthracycline-containing therapy for pediatric classical Hodgkin lymphoma.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Magnetic Resonance Imaging
- OTHER Survey Administration
- OTHER Electronic Health Record Review
- PROCEDURE Archive Sample Retrieval
Study Locations (20)
Florida
- Golisano Children's Hospital of Southwest Florida - Fort Myers
- Arnold Palmer Hospital for Children - Orlando
- Saint Joseph's Hospital/Children's Hospital-Tampa - Tampa
New York
- Albany Medical Center - Albany
- Roswell Park Cancer Institute - Buffalo
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Nationwide Children's Hospital - Columbus
Alabama
- USA Health Strada Patient Care Center - Mobile
Arizona
- Phoenix Childrens Hospital - Phoenix
Connecticut
- Yale University - New Haven
Delaware
- Alfred I duPont Hospital for Children - Wilmington
Georgia
- Children's Healthcare of Atlanta - Arthur M Blank Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2023-08-18 |
| Est. Completion | 2028-10-01 |
What NCT05705531 shows while recruiting
NCT05705531 is an observational study that tracks outcomes without assigning an intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap, below the 232-participant average among 9 other Classic Hodgkin Lymphoma trials with a reported enrollment target (18% lower).
The record links to 3 conditions, with Classic Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT05705531 names 20 study sites across 16 states, led by Florida, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT05705531 about?
NCT05705531 is a clinical study titled "A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma". This study assesses how blood cell growth patterns (clonal hematopoiesis) relate to heart health or cardiovascular disease (CVD) after treatment in patients with Hodgkin lymphoma. In some patients, cancer treatment at a young age may lead to later complications, including problems with heart health....
What is the current status of trial NCT05705531?
This trial is currently recruiting. The enrollment target is 190 participants. The study started on 2023-08-18. Estimated completion is 2028-10-01.
What conditions does trial NCT05705531 study?
This clinical trial studies the following conditions: Classic Hodgkin Lymphoma, Clonal Hematopoiesis, Cardiovascular Disorder.
What interventions are being tested in trial NCT05705531?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Survey Administration (OTHER), Electronic Health Record Review (OTHER), Archive Sample Retrieval (PROCEDURE).
Who is sponsoring clinical trial NCT05705531?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05705531 being conducted?
This trial has 20 study locations across Alabama, Arizona, Connecticut, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Classic Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05705531's enrollment target sits among peer trials
190 3rd of 9 higher than 7 of 9 other Classic Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Classic Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
RECRUITING · Phase 2
-
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
RECRUITING · Phase 2
-
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03257033 · 190 participants · Phase 3
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- NCT03642028 · 190 participants · Phase 4
Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
- NCT04015609 · 190 participants · NA
Psychotherapy Intervention for Latinos With Advanced Cancer
- NCT04284397 · 190 participants · Early Phase 1
Identification of Critical Thermal Environments for Aged Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI